Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of MK-0616 versus ezetimibe, bempedoic acid, or ezetimibe + bempedoic acid in adults with hypercholesterolemia
MOH_2024-07-31_013456Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enlicitide in hypercholesterolemia (4 arms), sponsored by Merck & Co. Primary endpoints: Safety of MK-0616 and LDL cholesterol lowering. Started Jul 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on MOH_2024-07-31_013456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-31_013456.